PRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy Volunteers

Coffey, G., Rani, A., Betz, A., Pak, Y., Haberstock-Debic, H., Pandey, A., Hollenbach, S., Gretler, D.D., Mant, T., Jurcevic, S. and Simha, U. (2017) PRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy Volunteers. Journal of Clinical Pharmacology, 57 (2). pp. 194-210. ISSN 0091-2700

[img]
Preview
PDF
JCPH-57-194.pdf - Published Version

Download (2MB) | Preview
[img]
Preview
PDF
JCPH-57-194-s001.pdf - Supplemental Material

Download (363kB) | Preview
[img]
Preview
PDF
JCPH-57-194-s002.pdf - Supplemental Material

Download (462kB) | Preview
[img]
Preview
PDF
JCPH-57-194-s003.pdf - Supplemental Material

Download (217kB) | Preview
[img] XML Word Processing Document (DOCX)
JCPH-57-194-s004.docx - Supplemental Material

Download (21kB)
Official URL: https://dx.doi.org/10.1002/jcph.794

Abstract

The spleen tyrosine kinase (SYK) regulates immune cell activation in response to engagement of a variety of receptors, making it an intriguing target for the treatment of inflammatory and autoimmune disorders as well as certain B-cell malignancies. We have previously reported on the discovery and preclinical characterization of PRT062607, a potent and highly selective inhibitor of SYK that exhibits robust anti-inflammatory activity in a variety of animal models. Here we present data from our first human studies aimed at characterizing the pharmacokinetics (PK), pharmacodynamics (PD), and safety of PRT062607 in healthy volunteers following single and multiple oral administrations. PRT062607 demonstrated a favorable PK profile and the ability to completely inhibit SYK activity in multiple whole-blood assays. The PD half-life in the more sensitive assays was approximately 24 hours and returned to predose levels by 72 hours. Selectivity for SYK was observed at all dose levels tested. Analysis of the PK/PD relationship indicated an IC50 of 324 nM for inhibition of B-cell antigen receptor-mediated B-cell activation and 205 nM for inhibition of FcεRI-mediated basophil degranulation. PRT062607 was safe and well tolerated across the entire range of doses. Clinical PK/PD was related to in vivo anti-inflammatory activity of PRT062607 in the rat collagen-induced arthritis model, which predicts that therapeutic concentrations may be safely achieved in humans for the treatment of autoimmune disease. PRT062607 has a desirable PK profile and is capable of safely, potently, and selectively suppressing SYK kinase function in humans following once-daily oral dosing.

Item Type: Article
Subjects: University of Westminster > Science and Technology
SWORD Depositor: repository@westminster.ac.uk
Depositing User: repository@westminster.ac.uk
Date Deposited: 17 Jul 2017 13:20
Last Modified: 17 Jul 2017 13:20
URI: http://westminsterresearch.wmin.ac.uk/id/eprint/19287

Actions (login required)

Edit Item (Repository staff only) Edit Item (Repository staff only)